Ignite Creation Date:
2025-12-24 @ 2:42 PM
Ignite Modification Date:
2026-01-01 @ 11:23 AM
Study NCT ID:
NCT04343859
Status:
UNKNOWN
Last Update Posted:
2023-11-09
First Post:
2020-03-23
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Sponsor:
Tianjin Chasesun Pharmaceutical Co., LTD
Organization:
Study Overview
Official Title:
A Phase I Clinical Trial of IMMH-010 in Patients With Advanced Malignant Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2022-12
Last Known Status:
ENROLLING_BY_INVITATION
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Phase I study of IMMH-010 in patients with advanced malignant solid tumors
Detailed Description:
To evaluate the safety and tolerability of single-dose and multi-dose IMMH-010 in patients with advanced solid tumors, et al.
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: